IMAX · Imax Corp
The AI's read
Rosenblatt raised Imax Corp's price target from $60 to $65 and kept a Buy rating. Imax closed at $52.66, so this analyst change reads as a favorable update for Imax.
Rosenblatt raised Imax's price target from $60 to $65 and kept a Buy, which is a favorable analyst view for Imax.
Rosenblatt raised Imax Corp's price target from $60 to $65 and kept a Buy rating. Imax closed at $52.66, so this analyst change reads as a favorable update for Imax.
Piper Sandler trimmed ServiceTitan's price target slightly but kept an Overweight rating, leaving competing signals that cancel each other.
Piper Sandler raised Braze's price target from $27 to $30 and kept an Overweight rating, which is a favorable analyst move for Braze.
Needham raised Varonis's price target from $50 to $55 and kept a Buy, which is a favorable analyst update for Varonis.
BTIG cut Boston Scientific's price target from $60 to $56 while keeping a Buy, which signals a reduced near-term expectation for Boston Scientific.
Wedbush raised Pharvaris's price target from $42 to $50 and kept an Outperform rating, which is a favorable analyst view for Pharvaris.
Follow Imax Corp (IMAX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IMAX